Clinical trial NCT03681197: Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility
Official title: Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Infertility
Keywords: metformin,unexplained infertility
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2018-09-21
Enrollment: 170
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to asses the effect of metformin on clinical pregnancy rate in women with unexplained infertility (randomized controlled trial).

This study will be conducted in infertility clinic,Ain Shams university maternity hospital,170 women with unexplained infertility will be enrolled in this study.

Statistical analysis of the data will be performed .

Detailed description: Metformin is usually used with induction regimen in patients with PCOS as it improves ovulation rate by direct effect on ovarian tissue,Metformin will be used in combination with clomiphene citrate in women with unexplained infertility with previous failed cycle to asses its efficacy on clinical pregnancy rate.

Study will be conducted in infertility clinic,Ain Shams university maternity hospital.Study population comprises women with unexplained infertility aged 20-35 years with total sample size of 170 who willbe randomized into two groups with 85 women in each group.

Group A:is case group who will receive metformin plus clomiphene citrate. Group B:is control group who will receive clomiphene citrate plus placebo. Metformin will be started at time of booking and will be continued till pregnancy is confirmed in a dose of 850 mg twice daily in form of tablet.

Vaginal ultrasound is done for all in day 2 to exclude presence of ovarian cyst and to identify normal appearance of ovaries,then folliculometry on day 9 followed by serial folliculometry every other day till reaching dominant follicle 18 mm or more where HCG intramuscular injection will be given in a dose of 10000 iu .

serum pregnancy test will be done after 16 days. Transvaginal ulterasound will be done on day 35.

Eligibility criteria: Inclusion Criteria:

* Age 20-35 years old.
* BMI 20-\<30
* FSH 12 IU/L or less
* Normal transvaginal ulterasound(normal uterus and ovaries with no congenital anomalies).
* Patent fallopian tubes assesd by hysterosalpingogram or laparoscopy.
* Normal semen analysis.
* Infertile women with history of previous failed induction cycle.

Exclusion Criteria:

* Women younger than 20 or elder than 35 years old.
* Women with BMI equal to or more than 30.
* Uncorrected congenital or acquired uterine anomaly.
* Other causes of infertility rather than unexplained infertility.
* Patient with Diabetes Mellitus.

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: one cycle for each woman (28 days in average)
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Elham Raafat Mohamed
Study officials:
affiliation: Ain Shams Maternity Hospital
name: Sarah S Moawad, Lecturer
role: STUDY_DIRECTOR
affiliation: Ain Shams Maternity Hospital
name: Ahmed M Bahaa Eldin, Professor
role: STUDY_DIRECTOR
affiliation: Ain Shams Maternity Hospital
name: Hisham M Fathy, Professor
role: STUDY_DIRECTOR
References: